Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2

Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear importation in the case of lentiviruses and integrati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Viruses-Basel 2024-10, Vol.16 (10)
Hauptverfasser: Kiarie, I.W, Hoffka, G, Laporte, Manon, Leyssen, Pieter, Neyts, Johan, Tőzsér, J, Mahdi, M
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 10
container_start_page
container_title Viruses-Basel
container_volume 16
creator Kiarie, I.W
Hoffka, G
Laporte, Manon
Leyssen, Pieter
Neyts, Johan
Tőzsér, J
Mahdi, M
description Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear importation in the case of lentiviruses and integration targeting events; hence, targeting the integrase and the viral capsid is a favorable therapeutic strategy. While integrase strand transfer inhibitors (INSTIs) are recommended as first-line regimens given their high efficacy and tolerability, lenacapavir is the first capsid inhibitor and the newest addition to the HIV treatment arsenal. These inhibitors are however designed for treatment of HIV-1 infection, and their efficacy against HIV-2 remains widely understudied and inconclusive, supported only by a few limited phenotypic susceptibility studies. We therefore carried out inhibition profiling of a panel of second-generation INSTIs and lenacapavir against HIV-2 in cell culture, utilizing pseudovirion inhibition profiling assays. Our results show that the tested INSTIs and lenacapavir exerted excellent efficacy against ROD-based HIV-2 integrase. We further evaluated the efficacy of raltegravir and other INSTIs against different variants of SARS-CoV-2; however, contrary to previous in silico findings, the inhibitors did not demonstrate significant antiviral activity.
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_20_500_12942_750743</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20_500_12942_750743</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_20_500_12942_7507433</originalsourceid><addsrcrecordid>eNqVjk1OwzAQhSMEEqVwB68RQc5fIy-rKKiVWDUVW2vq2KkhsiN7GpUrcUoSC6ksYTMzmu-9eXMVLRLGWJyzpLj-Nd9Gd96_U7paMVouoq9aKS1AfBKryNag7Bx4SRp0YFqyn6pX0k3kqA8arfNk3uNRkgoGr9sLIa_SgIABRu0IdKCNR7LZvsXpU_DU56G3TpsuuKdYKXAO3UEfUmebNQGuBepRY_ipWe-auLLTmfvoRkHv5cNPX0aPL_W-2sQfp16eRml46wcQkqeUF5TyJGV5ysuClnmW_VP8_GcxxzNm31k4cFw</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2</title><source>Lirias (KU Leuven Association)</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Kiarie, I.W ; Hoffka, G ; Laporte, Manon ; Leyssen, Pieter ; Neyts, Johan ; Tőzsér, J ; Mahdi, M</creator><creatorcontrib>Kiarie, I.W ; Hoffka, G ; Laporte, Manon ; Leyssen, Pieter ; Neyts, Johan ; Tőzsér, J ; Mahdi, M</creatorcontrib><description>Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear importation in the case of lentiviruses and integration targeting events; hence, targeting the integrase and the viral capsid is a favorable therapeutic strategy. While integrase strand transfer inhibitors (INSTIs) are recommended as first-line regimens given their high efficacy and tolerability, lenacapavir is the first capsid inhibitor and the newest addition to the HIV treatment arsenal. These inhibitors are however designed for treatment of HIV-1 infection, and their efficacy against HIV-2 remains widely understudied and inconclusive, supported only by a few limited phenotypic susceptibility studies. We therefore carried out inhibition profiling of a panel of second-generation INSTIs and lenacapavir against HIV-2 in cell culture, utilizing pseudovirion inhibition profiling assays. Our results show that the tested INSTIs and lenacapavir exerted excellent efficacy against ROD-based HIV-2 integrase. We further evaluated the efficacy of raltegravir and other INSTIs against different variants of SARS-CoV-2; however, contrary to previous in silico findings, the inhibitors did not demonstrate significant antiviral activity.</description><identifier>ISSN: 1999-4915</identifier><identifier>EISSN: 1999-4915</identifier><language>eng</language><publisher>MDPI AG</publisher><ispartof>Viruses-Basel, 2024-10, Vol.16 (10)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,777,781,27841</link.rule.ids></links><search><creatorcontrib>Kiarie, I.W</creatorcontrib><creatorcontrib>Hoffka, G</creatorcontrib><creatorcontrib>Laporte, Manon</creatorcontrib><creatorcontrib>Leyssen, Pieter</creatorcontrib><creatorcontrib>Neyts, Johan</creatorcontrib><creatorcontrib>Tőzsér, J</creatorcontrib><creatorcontrib>Mahdi, M</creatorcontrib><title>Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2</title><title>Viruses-Basel</title><description>Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear importation in the case of lentiviruses and integration targeting events; hence, targeting the integrase and the viral capsid is a favorable therapeutic strategy. While integrase strand transfer inhibitors (INSTIs) are recommended as first-line regimens given their high efficacy and tolerability, lenacapavir is the first capsid inhibitor and the newest addition to the HIV treatment arsenal. These inhibitors are however designed for treatment of HIV-1 infection, and their efficacy against HIV-2 remains widely understudied and inconclusive, supported only by a few limited phenotypic susceptibility studies. We therefore carried out inhibition profiling of a panel of second-generation INSTIs and lenacapavir against HIV-2 in cell culture, utilizing pseudovirion inhibition profiling assays. Our results show that the tested INSTIs and lenacapavir exerted excellent efficacy against ROD-based HIV-2 integrase. We further evaluated the efficacy of raltegravir and other INSTIs against different variants of SARS-CoV-2; however, contrary to previous in silico findings, the inhibitors did not demonstrate significant antiviral activity.</description><issn>1999-4915</issn><issn>1999-4915</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVjk1OwzAQhSMEEqVwB68RQc5fIy-rKKiVWDUVW2vq2KkhsiN7GpUrcUoSC6ksYTMzmu-9eXMVLRLGWJyzpLj-Nd9Gd96_U7paMVouoq9aKS1AfBKryNag7Bx4SRp0YFqyn6pX0k3kqA8arfNk3uNRkgoGr9sLIa_SgIABRu0IdKCNR7LZvsXpU_DU56G3TpsuuKdYKXAO3UEfUmebNQGuBepRY_ipWe-auLLTmfvoRkHv5cNPX0aPL_W-2sQfp16eRml46wcQkqeUF5TyJGV5ysuClnmW_VP8_GcxxzNm31k4cFw</recordid><startdate>20241013</startdate><enddate>20241013</enddate><creator>Kiarie, I.W</creator><creator>Hoffka, G</creator><creator>Laporte, Manon</creator><creator>Leyssen, Pieter</creator><creator>Neyts, Johan</creator><creator>Tőzsér, J</creator><creator>Mahdi, M</creator><general>MDPI AG</general><scope>FZOIL</scope></search><sort><creationdate>20241013</creationdate><title>Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2</title><author>Kiarie, I.W ; Hoffka, G ; Laporte, Manon ; Leyssen, Pieter ; Neyts, Johan ; Tőzsér, J ; Mahdi, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_20_500_12942_7507433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kiarie, I.W</creatorcontrib><creatorcontrib>Hoffka, G</creatorcontrib><creatorcontrib>Laporte, Manon</creatorcontrib><creatorcontrib>Leyssen, Pieter</creatorcontrib><creatorcontrib>Neyts, Johan</creatorcontrib><creatorcontrib>Tőzsér, J</creatorcontrib><creatorcontrib>Mahdi, M</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>Viruses-Basel</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kiarie, I.W</au><au>Hoffka, G</au><au>Laporte, Manon</au><au>Leyssen, Pieter</au><au>Neyts, Johan</au><au>Tőzsér, J</au><au>Mahdi, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2</atitle><jtitle>Viruses-Basel</jtitle><date>2024-10-13</date><risdate>2024</risdate><volume>16</volume><issue>10</issue><issn>1999-4915</issn><eissn>1999-4915</eissn><abstract>Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear importation in the case of lentiviruses and integration targeting events; hence, targeting the integrase and the viral capsid is a favorable therapeutic strategy. While integrase strand transfer inhibitors (INSTIs) are recommended as first-line regimens given their high efficacy and tolerability, lenacapavir is the first capsid inhibitor and the newest addition to the HIV treatment arsenal. These inhibitors are however designed for treatment of HIV-1 infection, and their efficacy against HIV-2 remains widely understudied and inconclusive, supported only by a few limited phenotypic susceptibility studies. We therefore carried out inhibition profiling of a panel of second-generation INSTIs and lenacapavir against HIV-2 in cell culture, utilizing pseudovirion inhibition profiling assays. Our results show that the tested INSTIs and lenacapavir exerted excellent efficacy against ROD-based HIV-2 integrase. We further evaluated the efficacy of raltegravir and other INSTIs against different variants of SARS-CoV-2; however, contrary to previous in silico findings, the inhibitors did not demonstrate significant antiviral activity.</abstract><pub>MDPI AG</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1999-4915
ispartof Viruses-Basel, 2024-10, Vol.16 (10)
issn 1999-4915
1999-4915
language eng
recordid cdi_kuleuven_dspace_20_500_12942_750743
source Lirias (KU Leuven Association); DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central
title Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A07%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Integrase%20Strand%20Transfer%20Inhibitors%20and%20the%20Capsid%20Inhibitor%20Lenacapavir%20against%20HIV-2,%20and%20Exploring%20the%20Effect%20of%20Raltegravir%20on%20the%20Activity%20of%20SARS-CoV-2&rft.jtitle=Viruses-Basel&rft.au=Kiarie,%20I.W&rft.date=2024-10-13&rft.volume=16&rft.issue=10&rft.issn=1999-4915&rft.eissn=1999-4915&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E20_500_12942_750743%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true